SLDB Stock Forecast: Solid Biosciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$6.25
−2.95% on the day

The 15 Wall Street analysts covering Solid Biosciences, Inc. hold a median 12-month price target of $19 — +196.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 43 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$697.6M
Ticker Nerd rank
43/ 100
Median analyst target
$19
Analysts covering
15
Revenue$0.0
Operating income−$57.4M
Net income−$54.8M
Free cash flow−$52.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.6%
1M
−2.3%
YTD
+10.8%
1Y
+40.1%
From 52W high
−43.9%
From 52W low
+40.1%
$4
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Solid Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
43/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
72
Revisions
65
Growth
50
Value
46
Accruals
40
Volatility
38
Issuance
35
Quality
31

Momentum (72): The shares have been drifting up relative to others.

Quality (31): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SLDB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SLDB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26SLDBHigh $26Median $19Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
15
Buy
0
Hold
0
Sell
$11
Low
$19
Median
$26
High

The green dot is the last close — the median target sits +196.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Nov 2026William BlairAssumesOutperform—
15 Oct 2026UBSInitiatesBuy$20
16 Sept 2026RBC CapitalInitiatesOutperform$18
14 Sept 2026HC Wainwright & Co.ReiteratesBuy$25
27 Aug 2026Cantor FitzgeraldMaintainsOverweight$16 → $26
21 Aug 2026Truist SecuritiesMaintainsBuy$16 → $20
3 June 2026HC Wainwright & Co.MaintainsBuy$20 → $25
18 May 2026WedbushReiteratesOutperform—
13 May 2026Piper SandlerMaintainsOverweight—
13 May 2026WedbushMaintainsOutperform—
25 Mar 2026JP MorganMaintainsOverweight—
23 Mar 2026HC Wainwright & Co.ReiteratesBuy—
20 Mar 2026Chardan CapitalMaintainsBuy—
20 Mar 2026GuggenheimInitiatesBuy—
20 Mar 2026NeedhamReiteratesBuy—
12 Mar 2026Chardan CapitalMaintainsBuy—
12 Mar 2026WedbushMaintainsOutperform—
11 Mar 2026WedbushReiteratesOutperform—
9 Feb 2026NeedhamReiteratesBuy—
14 Jan 2026NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SLDB.

Market Radar

This page is one stock. Monday covers all of them.

SLDB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SLDB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Solid Biosciences, Inc. returned +40.1% against +6.9% for the S&P 500, dividends included.

SLDB vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26SLDBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SLDB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
7
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.0×

Cheaper than 43% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−76.9%

Higher than 16% of US stocks

Return on assets
−41.8%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Solid Biosciences, Inc. has a market value of $697.6M and an enterprise value of $368.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$207.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$187.8M.

  • Solid Biosciences, Inc. spent $13.6M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 105.1M.

  • Solid Biosciences, Inc. employs 121 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

SLDB and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SLDBSolid Biosciences, Inc.$697.6M43
ATTOAttovia Therapeutics, Inc.$688.2M4
AURAAura Biosciences, Inc.$710.3M61
LXRXLexicon Pharmaceuticals, Inc.$680.8M69
OABIOmniAb, Inc.$677.5M99
APMDApnimed, Inc.$669.7M4
NVCTNuvectis Pharma, Inc.$666.8M50

Take a look at SLDB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Solid Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SLDB

What is the SLDB stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Solid Biosciences, Inc. have a median 12-month price target of $19, with estimates ranging from $11 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SLDB stock a buy right now?

Of the 15 analysts covering Solid Biosciences, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Solid Biosciences, Inc. 43 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SLDB?

As at 21 Nov 2026, Solid Biosciences, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (72 of 100).

Will SLDB stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +196.0% from the last close, and Ticker Nerd's factor model ranks Solid Biosciences, Inc. 43 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SLDB stock forecast for 2030?

No analyst covering Solid Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLDB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $26 over the next 12 months.

How has SLDB stock performed over the past year?

Solid Biosciences, Inc. returned +40.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Solid Biosciences, Inc. do?

Solid Biosciences Inc. is a precision genetic medicine company focused on developing gene therapy candidates for rare neuromuscular and cardiac diseases. Solid Biosciences Inc. advances a pipeline that includes programs for Duchenne muscular dystrophy, Friedreich’s ataxia, catecholaminergic polymorphic ventricular tachycardia, and certain forms of dilated cardiomyopathy.

Company

About Solid Biosciences, Inc.

Solid Biosciences Inc. is a precision genetic medicine company focused on developing gene therapy candidates for rare neuromuscular and cardiac diseases. Solid Biosciences Inc. advances a pipeline that includes programs for Duchenne muscular dystrophy, Friedreich’s ataxia, catecholaminergic polymorphic ventricular tachycardia, and certain forms of dilated cardiomyopathy. Its work centers on addressing severe genetic disorders through targeted therapies designed to act on the underlying disease biology rather than on symptoms alone. The company serves the biotechnology and rare-disease markets, where its research and clinical development efforts are aimed at conditions with significant unmet medical need. Headquartered in Charlestown, Massachusetts, Solid Biosciences Inc. operates as a life sciences company with a focus on translating genetic science into treatments for patients with serious inherited diseases.

CEO Mr. Alexander G. Cumbo · 121 employees · United States · https://www.solidbio.com